Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

This study is testing a three-drug combination — tafasitamab, lenalidomide, and venetoclax — for people with mantle cell lymphoma (a type of blood cancer) that has returned or stopped responding to prior treatment. **You may be eligible if...** - You are 18 or older with confirmed mantle cell lymphoma - Your lymphoma has come back or has not responded to at least one prior treatment - You are in need of treatment based on your doctor's assessment - Your blood counts and organ function are within acceptable ranges - You are willing to use effective contraception and comply with the study's medication safety program (REMS) **You may NOT be eligible if...** - You have had a recent stem cell transplant (within 90 days) or CAR T-cell therapy (within 90 days) - You have lymphoma in the brain or spinal cord - You are currently receiving other lymphoma treatment (excluding steroids) - You have HIV, active hepatitis B or C - You have significant heart disease (recent heart attack, severe heart failure) - You are pregnant or unwilling to use contraception - You cannot swallow oral medications Talk to your doctor to see if this trial is right for you.